Three Reasons Valeant (VRX) is Plunging Today

Valeant (VRX) Price Target Cut to $195 at Guggenheim; Thesis Intact

November 6, 2015 6:29 AM EST

Guggenheim analyst Louise Chen lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $195.00 (from $300.00) but maintained a Buy rating saying the investment thesis remains intact.

Chen commented, "We are lowering our PT for VRX to $195 from $300. The decrease in our PT is... More

Worst Case Valeant (VRX) is a Buy - Mizuho

November 5, 2015 3:13 PM EST

Mizuho Securities analyst Irina Koffler said worse case analysis and Valeant Pharmaceuticals (NYSE: VRX) is a Buy. The firm reiterated a Buy rating and $155 price target.

The stock is no longer trading on fundamentals in our view. We look at a liquidation valuation in the extreme case that management is ousted and the business is put up for sale under distressed conditions. We conclude shares are undervalued and reiterate our BUY rating

Key points:

We try to remain rational and reiterate our BUY rating: We understand the... More

Valeant Pharma (VRX) Board Has Full Confidence in Mike Pearson - CNBC

November 5, 2015 1:53 PM EST

Valeant Pharma (NYSE: VRX) says in statement CEO Mike Pearson continues to have board's full confidence; "he remains focused on running the business" - CNBC's Tirrel

... More

HedgEye says Valeant Pharma (VRX) may fall another 75%

November 5, 2015 1:14 PM EST

HedgEye says Valeant Pharma (NYSE: VRX) may fall another 75%

LINK

... More

BMO Capital Sees Valeant (VRX) Weakness Related to Ackman Comments that Pearson Might Have to Go

November 5, 2015 11:47 AM EST

BMO Capital analyst Alex Arfaei weighed in on today's weakness in Valeant Pharmaceuticals (NYSE: VRX), saying they suspect that the decline is primarily related to Mr. Ackmans comments published today in the Wall Street Journal suggesting that Valeants CEO, Mr. Pearson, might have to go.

The article discloses conversations between Mr. Ackman and Valeants lead director, Robert Ingram. According to the article, Mr. Ackman told Mr. Ingram "If Mike [Pearson] hides in the bunker on this, he cant be CEO." Moreover, according to the article, Mr. Ackman told Mr.... More

Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows

November 5, 2015 10:58 AM EST

By Svea Herbst-Bayliss and Caroline Humer

BOSTON/NEW YORK (Reuters) - Billionaire investor Bill Ackman expressed confidence in Valeant Pharmaceuticals International Inc's chief executive on Thursday as shares in the drugmaker fell as much as 20 percent to their lowest level since 2013 on concerns over its business practices.

Valeant (NYSE: VRX)(NYSE: VRX) CEO Michael Pearson has come under increasing pressure as the company's stock plunged from $263.70 on Aug. 5 to below $80 on Thursday on scrutiny over high price markups for its drugs and accusations it used a specialty pharmacy,... More

Valeant (VRX) In Free Fall as Large Holders May Finally Be Crying Uncle

November 5, 2015 10:42 AM EST

Shares of embattled pharmaceutical company Valeant Pharma (NYSE: VRX) are in free fall Thursday. Shares last traded down 18% to $75. All the talk on Wall Street is that large shareholders are finally throwing in the towel, forced or otherwise, following allegations of prescription and medicare... More

Ackman Stocks Trade Lower on Valeant (VRX) Free-Fall

November 5, 2015 10:25 AM EST

A number of Bill Ackman stocks are getting hit with today's free fall in Valeant (NYSE: VRX) (-16%): Zoetis (NYSE: ZTS) (-3%), Mondelez (NASDAQ: MDLZ) (-0.5%), Air Product (NYSE:... More

Valeant Pharma (VRX) Plunges Over 16%

November 5, 2015 10:12 AM EST

Sell-off in Valeant Pharma (NYSE: VRX) intensifies. Shares down 16%. Chatter liquidation by large holders

... More

Valeant Pharma (VRX) Breaks Support at $88.50

November 5, 2015 9:49 AM EST

Valeant Pharma (NYSE: VRX) shares declined Thursday after shares broke through support at $88.50. The level had held since Oct. 21.

... More